Arlington Partners LLC Boosts Position in Thermo Fisher Scientific Inc. $TMO

Key Points

• Arlington Partners LLC increased its stake in Thermo Fisher Scientific by 34.2% during Q2, holding shares valued at $4.36 million.
• Thermo Fisher Scientific reported Q2 earnings of $5.36 EPS, surpassing estimates and achieving a revenue of $10.86 billion, up 2.9% year-over-year.
• The company is set to pay a quarterly dividend of $0.43 per share on October 15th, with a dividend yield of 0.4%.

Arlington Partners LLC grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 34.2% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,763 shares of the medical research company's stock after buying an additional 2,744 shares during the quarter. Arlington Partners LLC's holdings in Thermo Fisher Scientific were worth $4,364,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. LaFleur & Godfrey LLC grew its position in shares of Thermo Fisher Scientific by 0.3% in the second quarter. LaFleur & Godfrey LLC now owns 31,017 shares of the medical research company's stock valued at $12,576,000 after purchasing an additional 78 shares during the period. U.S. Capital Wealth Advisors LLC lifted its position in shares of Thermo Fisher Scientific by 5.6% in the second quarter. U.S. Capital Wealth Advisors LLC now owns 1,779 shares of the medical research company's stock valued at $721,000 after acquiring an additional 95 shares in the last quarter. Border to Coast Pensions Partnership Ltd increased its position in shares of Thermo Fisher Scientific by 50.3% during the second quarter. Border to Coast Pensions Partnership Ltd now owns 141,133 shares of the medical research company's stock worth $57,224,000 after purchasing an additional 47,220 shares in the last quarter. Avanza Fonder AB boosted its position in Thermo Fisher Scientific by 5.1% during the second quarter. Avanza Fonder AB now owns 27,526 shares of the medical research company's stock worth $11,161,000 after acquiring an additional 1,326 shares during the last quarter. Finally, Atle Fund Management AB boosted its holdings in shares of Thermo Fisher Scientific by 6.2% during the 2nd quarter. Atle Fund Management AB now owns 24,266 shares of the medical research company's stock worth $9,839,000 after purchasing an additional 1,409 shares during the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO traded down $5.04 during midday trading on Monday, reaching $474.54. 2,352,185 shares of the stock were exchanged, compared to its average volume of 1,557,193. The company has a market capitalization of $179.19 billion, a price-to-earnings ratio of 27.45, a PEG ratio of 2.56 and a beta of 0.75. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.93 and a quick ratio of 1.50. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $623.77. The business's 50-day moving average price is $472.99 and its 200 day moving average price is $448.55.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Wednesday, July 23rd. The medical research company reported $5.36 EPS for the quarter, beating analysts' consensus estimates of $5.22 by $0.14. The business had revenue of $10.86 billion for the quarter, compared to analysts' expectations of $10.68 billion. Thermo Fisher Scientific had a net margin of 15.24% and a return on equity of 16.82%. The company's quarterly revenue was up 2.9% on a year-over-year basis. During the same period in the previous year, the company posted $5.37 EPS. Thermo Fisher Scientific has set its Q3 2025 guidance at 5.460-5.510 EPS. FY 2025 guidance at 22.220-22.840 EPS. On average, sell-side analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, October 15th. Shareholders of record on Monday, September 15th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Monday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is 9.95%.

Insider Transactions at Thermo Fisher Scientific

In related news, CAO Joseph R. Holmes sold 385 shares of the stock in a transaction dated Friday, August 29th. The shares were sold at an average price of $492.63, for a total transaction of $189,662.55. Following the completion of the transaction, the chief accounting officer directly owned 2,319 shares of the company's stock, valued at $1,142,408.97. This represents a 14.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Marc N. Casper sold 400 shares of the stock in a transaction that occurred on Friday, September 5th. The stock was sold at an average price of $500.50, for a total value of $200,200.00. Following the transaction, the chief executive officer directly owned 113,762 shares of the company's stock, valued at approximately $56,937,881. This trade represents a 0.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 30,066 shares of company stock worth $14,182,963 over the last 90 days. 0.33% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of analyst reports. Robert W. Baird upped their price objective on shares of Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an "outperform" rating in a report on Thursday, July 24th. Hsbc Global Res cut Thermo Fisher Scientific from a "strong-buy" rating to a "hold" rating in a report on Thursday, July 24th. Wells Fargo & Company decreased their price target on Thermo Fisher Scientific from $570.00 to $565.00 and set an "overweight" rating on the stock in a research note on Thursday, July 24th. Barclays upgraded shares of Thermo Fisher Scientific from an "equal weight" rating to an "overweight" rating and lifted their price target for the company from $490.00 to $550.00 in a research report on Thursday, September 11th. Finally, Evercore ISI dropped their price objective on Thermo Fisher Scientific from $500.00 to $480.00 and set an "outperform" rating for the company in a research note on Tuesday, July 8th. Sixteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $588.35.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.